China strives to lower cost of cancer drugs as disease rates soar
Should there be a different review of NICE as part of a successor PPRS?
The changing landscape for drug pricing and some pointers for the UK life sciences sector.
An examination of the range of different trends and forces that are acting on the pharmaceutical sector.
PPRS impact: has it kept the branded medicines bill within affordable limits?
Has the UK PPRS scheme met its five objectives?